

SNDX-5613

Chemical Properties


CAS No. : 2169919-21-3

Formula: C32H47FN6O4S

Molecular Weight: 630.82

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.
Targets(IC50)	Epigenetic Reader Domain,Histone Methyltransferase
In vitro	METHODS: Primary patient-derived NUP98-r AML cells were treated with Revumenib (SNDX-5613) (2, 46, 125 nM) and cell viability was measured. RESULTS Revumenib inhibited the growth of primary patient-derived NUP98-r AML cells. [3]
In vivo	SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.SNDX-5613 shows in vivo plasma(IC50 : 53 nM) .

Solubility Information

Solubility	DMSO: 52 mg/mL (82.43 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 4 mg/mL (6.34 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5852 mL	7.9262 mL	15.8524 mL
5 mM	0.317 mL	1.5852 mL	3.1705 mL
10 mM	0.1585 mL	0.7926 mL	1.5852 mL
50 mM	0.0317 mL	0.1585 mL	0.317 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Issa GC, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. *Nature*. 2023 Mar; 615(7954):920-924.

A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).

Rasouli M, et al. The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML. *Hemasphere*. 2023 Jul 27;7(8):e935.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481